In the SUPREMO trial, what proportion of patients in the chest wall irradiation arm also had coverage of the supraclavicular fossa or internal mammary nodes?
What is the rate of major response to induction chemoimmunotherapy in patients with anal cancer in the INTERACT-ION trial?
Can the parotids be spared during whole brain radiation with conventional 3D fields?
Answers
12% and 1.5%, respectively. Chest wall irradiation did not significantly improve OS or DFS at 10 years.
75% had >30% tumor reduction, <10% residual tumor cells on biopsy, and no residual HPV ctDNA. They received radiation alone with involved nodal irradiation.
Yes, this trial showed that by contouring and partially blocking the parotids acute xerostomia could be reduced. | QuadShot News
What is the rate of major response to induction chemoimmunotherapy in patients with anal cancer in the INTERACT-ION trial?
Can the parotids be spared during whole brain radiation with conventional 3D fields?
Answers
12% and 1.5%, respectively. Chest wall irradiation did not significantly improve OS or DFS at 10 years.
75% had >30% tumor reduction, <10% residual tumor cells on biopsy, and no residual HPV ctDNA. They received radiation alone with involved nodal irradiation.
Yes, this trial showed that by contouring and partially blocking the parotids acute xerostomia could be reduced. | QuadShot News